WO2002014319A3 - Heterocyclic compounds useful as inhibitors of tyrosine kinases - Google Patents
Heterocyclic compounds useful as inhibitors of tyrosine kinases Download PDFInfo
- Publication number
- WO2002014319A3 WO2002014319A3 PCT/US2001/024390 US0124390W WO0214319A3 WO 2002014319 A3 WO2002014319 A3 WO 2002014319A3 US 0124390 W US0124390 W US 0124390W WO 0214319 A3 WO0214319 A3 WO 0214319A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- inhibitors
- useful
- tyrosine kinases
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002519459A JP5000068B2 (en) | 2000-08-11 | 2001-08-02 | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
MXPA03001306A MXPA03001306A (en) | 2000-08-11 | 2001-08-02 | Heterocyclic compounds useful as inhibitors of tyrosine kinases. |
DE60132702T DE60132702T2 (en) | 2000-08-11 | 2001-08-02 | Heterocyclic compounds as inhibitors of tyrosine kinases |
EP01957425A EP1309596B1 (en) | 2000-08-11 | 2001-08-02 | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
CA002417635A CA2417635C (en) | 2000-08-11 | 2001-08-02 | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22472400P | 2000-08-11 | 2000-08-11 | |
US60/224,724 | 2000-08-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002014319A2 WO2002014319A2 (en) | 2002-02-21 |
WO2002014319A3 true WO2002014319A3 (en) | 2002-08-01 |
Family
ID=22841899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/024390 WO2002014319A2 (en) | 2000-08-11 | 2001-08-02 | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
Country Status (9)
Country | Link |
---|---|
US (2) | US6489328B2 (en) |
EP (1) | EP1309596B1 (en) |
JP (1) | JP5000068B2 (en) |
AT (1) | ATE385498T1 (en) |
CA (1) | CA2417635C (en) |
DE (1) | DE60132702T2 (en) |
ES (1) | ES2299501T3 (en) |
MX (1) | MXPA03001306A (en) |
WO (1) | WO2002014319A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005536533A (en) * | 2002-08-08 | 2005-12-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Substituted benzimidazole compounds |
US7135484B2 (en) * | 2002-08-14 | 2006-11-14 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
MXPA05001726A (en) * | 2002-08-14 | 2005-05-27 | Abbott Lab | Azabicyclic compounds are central nervous system active agents. |
WO2004030635A2 (en) * | 2002-10-03 | 2004-04-15 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
AU2004240772B2 (en) * | 2003-05-22 | 2011-04-28 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP1809614B1 (en) * | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
CA2578283A1 (en) | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
ES2400287T3 (en) * | 2005-03-14 | 2013-04-08 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions and methods of use as beta-secretase inhibitors |
WO2006101783A2 (en) * | 2005-03-15 | 2006-09-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
US8541457B2 (en) * | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
BRPI0606172A2 (en) * | 2005-06-08 | 2009-06-02 | Targegen Inc | methods and compositions for treating eye disorders |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
JP5191391B2 (en) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007127366A2 (en) * | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
WO2008063668A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CN103249306A (en) * | 2010-11-28 | 2013-08-14 | Mapi医药公司 | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium |
CN103298816A (en) | 2010-12-17 | 2013-09-11 | 内尔维阿诺医学科学有限公司 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
KR101934651B1 (en) * | 2017-10-19 | 2019-01-02 | 가톨릭대학교 산학협력단 | Composition for Preventing or Treating TNF-mediated Disease Comprising Novel Derivatives and Method for Inhibiting TNF-activity with the Same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4176184A (en) * | 1977-07-21 | 1979-11-27 | Boehringer Ingelheim Gmbh | Imidazoisoquinoline-diones and salts thereof |
EP0322746A1 (en) * | 1987-12-30 | 1989-07-05 | Orion Corporation Limited | Heterocyclic compounds |
WO1998028281A1 (en) * | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
WO1999024035A1 (en) * | 1997-11-10 | 1999-05-20 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP0991628B1 (en) | 1997-05-28 | 2005-01-12 | Aventis Pharmaceuticals Inc | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
-
2001
- 2001-08-02 WO PCT/US2001/024390 patent/WO2002014319A2/en active IP Right Grant
- 2001-08-02 ES ES01957425T patent/ES2299501T3/en not_active Expired - Lifetime
- 2001-08-02 DE DE60132702T patent/DE60132702T2/en not_active Expired - Lifetime
- 2001-08-02 US US09/921,510 patent/US6489328B2/en not_active Expired - Lifetime
- 2001-08-02 CA CA002417635A patent/CA2417635C/en not_active Expired - Fee Related
- 2001-08-02 JP JP2002519459A patent/JP5000068B2/en not_active Expired - Fee Related
- 2001-08-02 AT AT01957425T patent/ATE385498T1/en active
- 2001-08-02 EP EP01957425A patent/EP1309596B1/en not_active Expired - Lifetime
- 2001-08-02 MX MXPA03001306A patent/MXPA03001306A/en unknown
-
2002
- 2002-10-15 US US10/271,222 patent/US6844435B2/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4176184A (en) * | 1977-07-21 | 1979-11-27 | Boehringer Ingelheim Gmbh | Imidazoisoquinoline-diones and salts thereof |
EP0322746A1 (en) * | 1987-12-30 | 1989-07-05 | Orion Corporation Limited | Heterocyclic compounds |
WO1998028281A1 (en) * | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
WO1999024035A1 (en) * | 1997-11-10 | 1999-05-20 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
Non-Patent Citations (4)
Title |
---|
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; AGARWAL, SHIV K. ET AL: "Segregation of activity profile in benzimidazoles: effect of spacers at 5(6)-position of methyl benzimidazole-2-carbamates", XP002190317, retrieved from STN Database accession no. 120:124172 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KUMAR, SHIV ET AL: "Possible anthelmintic agents: syntheses of various imidazoquinazolinone carbamates", XP002190316, retrieved from STN Database accession no. 97:38906 * |
INDIAN J. CHEM., SECT. B (1981), 20B(12), 1068-71 * |
Z. NATURFORSCH., C: BIOSCI. (1993), 48(11-12), 829-38 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002014319A2 (en) | 2002-02-21 |
CA2417635C (en) | 2008-02-05 |
US6844435B2 (en) | 2005-01-18 |
US20030207902A1 (en) | 2003-11-06 |
ATE385498T1 (en) | 2008-02-15 |
DE60132702D1 (en) | 2008-03-20 |
JP5000068B2 (en) | 2012-08-15 |
JP2004506636A (en) | 2004-03-04 |
EP1309596B1 (en) | 2008-02-06 |
CA2417635A1 (en) | 2002-02-21 |
EP1309596A2 (en) | 2003-05-14 |
DE60132702T2 (en) | 2009-03-19 |
US20020119975A1 (en) | 2002-08-29 |
MXPA03001306A (en) | 2003-10-15 |
ES2299501T3 (en) | 2008-06-01 |
US6489328B2 (en) | 2002-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002014319A3 (en) | Heterocyclic compounds useful as inhibitors of tyrosine kinases | |
WO2001025238A3 (en) | Heterocyclic compounds useful as inhibitors of tyrosine kinases | |
WO2005016918A3 (en) | Heterocyclic n-aryl carboxamides as cytokine inhibitors | |
GEP20094804B (en) | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | |
AU2735201A (en) | Pyrimidine and triazine kinase inhibitors | |
YU37904A (en) | Benzimidazoles useful as protein kinase inhibitors | |
WO2006062982A3 (en) | Urea inhibitors of map kinases | |
WO2006050109A3 (en) | Novel kinase inhibitors | |
WO2006014405A3 (en) | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | |
TW200602313A (en) | Anti-cytokine heterocyclic compounds | |
WO2007071752A3 (en) | Pyrimidinyl aryl urea derivatives being fgf inhibitors | |
NO20072795L (en) | Pyrazole [1,5-a] pyrimidines useful as inhibitors of protein kinases | |
WO2006131835A3 (en) | Heterocyclic triazines as hypoxic selective protein kinase inhibitors | |
WO2006065601A3 (en) | Inhibitors of akt activity | |
YU84603A (en) | Novel tyrosine kinase inhibitors | |
WO2006062984A3 (en) | Inhibitors of protein kinases | |
WO2007056164A3 (en) | Aminopyrimidines useful as kinase inhibitors | |
WO2005077344A3 (en) | Hydantoin derivatives as inhibitors of cellular necrosis | |
WO2005115991A8 (en) | Anti-cytokine heterocyclic compounds | |
ATE532781T1 (en) | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | |
AU3864500A (en) | Substituted aza-oxindole derivatives | |
WO2007076228A8 (en) | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders | |
MXPA05013076A (en) | Isoindolin-1-one compounds as kinase inhibitors. | |
WO2004092144A3 (en) | Quinazoline compounds useful as p38 kinase inhibitors | |
WO2005056535A8 (en) | 1,2,3-triazole amide derivatives as inhibitors of cytokine production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2417635 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001957425 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002519459 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/001306 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 2001957425 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001957425 Country of ref document: EP |